利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.019 秒)

    BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF
    3.
    发明申请
    BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF 有权

    公开(公告)号：US20220275081A1

    公开(公告)日：2022-09-01

    申请号：US17286429

    申请日：2019-10-17

    申请人： GOOD T CELLS, INC.

    发明人： Jung Ho Kim ,  Beom Seok Kim

    IPC分类号： C07K16/28 ,  A61P35/00

    摘要： Provided herein is a binding molecule capable of specifically binding to LRIG-1 protein, which is located on the surface of a regulatory T cell. Also provided is pharmaceutical composition comprising the binding molecule. Further provided are methods of treating a cancer using the binding molecule or pharmaceutical composition disclosed herein.

    Recombinant fusion protein of BAF57 and uses thereof
    5.
    发明授权
    Recombinant fusion protein of BAF57 and uses thereof 有权

    公开(公告)号：US11345729B2

    公开(公告)日：2022-05-31

    申请号：US16728216

    申请日：2019-12-27

    申请人： GOOD T CELLS, INC.

    发明人： Jung Ho Kim ,  Beom Seok Kim

    IPC分类号： C07K14/47

    摘要： The present disclosure relates to a novel recombinant BAF57 fusion protein and the use thereof as a composition capable of effectively preventing or treating inflammatory disease, immune-related disease or cancer.
    The fusion protein provided in the present disclosure may be delivered into cells, bind to BAF155 or other BAF complex subunit, and act as a competitive inhibitor of BAF57 present in the cell, thereby lowering the expression level of BAF57 by a protein degradation mechanism, thereby effectively preventing, ameliorating or treating various diseases such as inflammatory disease, immune-related disease or cancer.

    Binding molecule specific for Lrig-1 protein and use thereof
    7.
    发明授权
    Binding molecule specific for Lrig-1 protein and use thereof 有权

    公开(公告)号：US11999785B2

    公开(公告)日：2024-06-04

    申请号：US17672208

    申请日：2022-02-15

    申请人： GOOD T CELLS, INC.

    发明人： Jung Ho Kim ,  Beom Seok Kim

    IPC分类号： C07K16/28 ,  A61P35/00 ,  A61P37/06 ,  A61K39/00

    CPC分类号： C07K16/28 ,  A61P35/00 ,  A61P37/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76

    摘要： The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.

    Binding molecule specific for LRIG-1 protein and use thereof
    10.
    发明授权
    Binding molecule specific for LRIG-1 protein and use thereof 有权

    公开(公告)号：US11279756B2

    公开(公告)日：2022-03-22

    申请号：US16606220

    申请日：2018-04-18

    申请人： GOOD T CELLS, INC.

    发明人： Jung Ho Kim ,  Beom Seok Kim

    IPC分类号： C07K16/18 ,  C07K14/47 ,  C07K16/28 ,  A61P35/00 ,  A61P37/06 ,  A61K39/00

    摘要： The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.